Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 8, 2026CancersOpen Access

Oncologic and Surgical Outcomes After Short-Course Neoadjuvant CAPOX Plus Bevacizumab in High-Risk Colorectal Liver Metastases

View Full Paper
Ask AI
Bookmark
Share

Authors

YDYawen DongMTMadita M TschoeglFLFlorian Lehner

Discussion

Loading...

Member takes

Overview

Examines oncologic outcomes in high-risk colorectal liver metastases treated with neoadjuvant CAPOX and bevacizumab, suggesting its effectiveness.

Key Points

  • The research aims to assess the safety and efficacy of short-course neoadjuvant therapy using CAPOX and bevacizumab in patients with high-risk colorectal liver metastases.
  • Included patients with synchronous or metachronous colorectal liver metastases (CRLM)
  • Administered two cycles of neoadjuvant CAPOX plus bevacizumab
  • Conducted biochemical, radiologic, and pathologic response assessments
  • Analyzed survival outcomes and treatment tolerability
  • 57 patients included, with 65% having synchronous disease
  • 53.7% achieved over 50% reduction in tumor markers
  • Partial response observed in 31.6% and complete response in 1.7% of cases
  • Grade ≥3 adverse events occurred in 10.6% of patients, mainly neutropenia and diarrhea
  • Improved overall survival and recurrence-free survival in patients with tumors <5 cm and those receiving adjuvant therapy

Cite This Study

Dong et al. (2026) studied this question.

synapsesocial.com/papers/698828410fc35cd7a88479abhttps://doi.org/10.3390/cancers18030521
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Induction CAPOX as part of total neoadjuvant therapy for high-risk locally advanced rectal cancer: Long-term real-world outcomes from two centers.2026
  2. 2Neoadjuvant bevacizumab and chemoradiotherapy for Locally Advanced Rectal Cancer: long term outcomes of a multicentre study2026
  3. 3Short-course radiotherapy followed by ivonescimab and CAPOX as neoadjuvant therapy for locally advanced rectal cancer: A single-arm, phase II trial.2026
  4. 4Response to Letter to the Editor Entitled “Clarifying Treatment Compliance and Future Directions in Perioperative Chemotherapy for Resectable Colorectal Liver Metastases”2025
  5. 5Neoadjuvant FOLFOXIRI plus bevacizumab without radiotherapy for high-risk rectal cancer: multicentre phase II trial2025